Sweeteners: erythritol, xylitol and cardiovascular risk-friend or foe?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing physiological, genetic, and clinical data without systematic methodology
PubMed 40444390 · doi:10.1093/cvr/cvaf091
What was done
This narrative review synthesized physiological, metabolomic, genetic, and clinical literature on the health effects of sugar alcohols, focusing on erythritol and xylitol. The authors evaluated polyol metabolism, endogenous synthesis, gastrointestinal hormone responses such as glucagon-like peptide-1 release, pilot trials on platelet aggregation, Mendelian randomization studies, and safety profiles in critically ill patients.
What was found
The abstract provides no numerical data. It reports that erythritol and xylitol minimally impact glucose and insulin levels while stimulating gut hormones including glucagon-like peptide-1. Pilot trials suggest transient alterations in platelet aggregation, but Mendelian randomization analyses and studies in critically ill patients receiving large intravenous doses do not link sugar alcohols to significant cardiovascular risk.
Why it matters
This review contrasts preliminary concerns over polyol-induced platelet reactivity against genetic and clinical safety evidence, highlighting the confounding role of endogenous polyol production.
Limits
As a narrative review, the publication lacks systematic search criteria, quality appraisal, and meta-analytic pooling. The abstract omits all numerical data, sample sizes, and detailed study characteristics. The regulatory mechanisms and clinical implications of endogenous sugar alcohol production remain poorly understood.